Scarica l'app Stockscreener
8.615
2.56%
0.215
Precedente Chiudi:
$8.40
Aprire:
$8.46
Volume 24 ore:
150.58K
Relative Volume:
0.15
Capitalizzazione di mercato:
$485.00M
Reddito:
$27.46M
Utile/perdita netta:
$-46.05M
Rapporto P/E:
-6.6783
EPS:
-1.29
Flusso di cassa netto:
$-33.83M
1 W Prestazione:
+0.17%
1M Prestazione:
-3.42%
6M Prestazione:
-8.64%
1 anno Prestazione:
+7.82%
Intervallo 1D:
$8.46
$8.675
Intervallo di 1 settimana:
$8.25
$8.73
Portata 52W:
$6.19
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Nome
Zevra Therapeutics Inc
Settore
Industria
Telefono
(321) 939-3416
Indirizzo
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Compare ZVRA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
8.615 | 472.90M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
494.23 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
800.45 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
836.63 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.42 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
349.91 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-02 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-08 | Ripresa | Cantor Fitzgerald | Overweight |
| 2024-10-07 | Iniziato | Guggenheim | Buy |
| 2024-09-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-24 | Reiterato | Maxim Group | Buy |
| 2024-04-02 | Reiterato | Maxim Group | Buy |
| 2024-03-12 | Iniziato | William Blair | Outperform |
| 2023-03-17 | Iniziato | Maxim Group | Buy |
Mostra tutto
Zevra Therapeutics Inc Borsa (ZVRA) Ultime notizie
Neil F. McFarlane, Zevra Therapeutics president, sells $125k in shares - Investing.com Canada
Stock Analysis: What is the implied volatility of Zevra Therapeutics IncEarnings Growth Report & Technical Confirmation Alerts - baoquankhu1.vn
Zevra Therapeutics opens Nasdaq with bell ceremony - Traders Union
Zevra Therapeutics Rings the Opening Bell - Nasdaq
Will Zevra Therapeutics Inc. benefit from geopolitical trendsWeekly Profit Analysis & Expert Approved Momentum Ideas - mfd.ru
Responsive Playbooks and the ZVRA Inflection - Stock Traders Daily
Zevra Therapeutics, Inc. (ZVRA) Investor Outlook: Unpacking a 169.66% Potential Upside with Robust Revenue Growth - DirectorsTalk Interviews
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA in Patients with Neimann-Pick Disease Type C at the 22nd Annual WorthLDSymposium - marketscreener.com
ZVRA: Zevra Therapeutics Unveils Promising Data on Miplyffa at W - GuruFocus
Zevra Therapeutics Presents Positive Data on MIPLYFFA® for Niemann-Pick Disease Type C at WORLDSymposium™ 2026 - Quiver Quantitative
4 years of real-world data track MIPLYFFA in rare Niemann-Pick disease - Stock Titan
Timothy Sangiovanni Sells 3,000 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock - MarketBeat
Schafer Joshua, CCO of Zevra, sells $29,800 in ZVRA stock By Investing.com - Investing.com Australia
Schafer Joshua, CCO of Zevra, sells $29,800 in ZVRA stock - Investing.com
Zevra Therapeutics (NASDAQ:ZVRA) Insider Sells $29,801.25 in Stock - MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Insider Sells $40,026.39 in Stock - MarketBeat
Neil Mcfarlane Sells 91,000 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock - MarketBeat
Insider Selling: Zevra Therapeutics (NASDAQ:ZVRA) SVP Sells 1,750 Shares of Stock - MarketBeat
Zevra Therapeutics CEO McFarlane sells $853k in shares By Investing.com - Investing.com South Africa
Zevra Therapeutics CEO McFarlane sells $853k in shares - Investing.com
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 - The Manila Times
Published on: 2026-02-02 12:45:20 - baoquankhu1.vn
Portfolio Shifts: Can Zevra Therapeutics Inc maintain sales growthJuly 2025 Spike Watch & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Layoff Watch: Does Zevra Therapeutics Inc have declining or rising EPS2025 Growth vs Value & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Down 32.5% in January - MarketBeat
Is Zevra Therapeutics Inc. forming bullish engulfing patternsMarket Movement Recap & Expert Verified Stock Movement Alerts - mfd.ru
Zevra Therapeutics, Inc. (ZVRA) Stock Analysis: Exploring a Promising 154% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Understanding the Setup: (ZVRA) and Scalable Risk - Stock Traders Daily
Delaware Chancery Court Ruling Finds a Security Interest is a “Transfer” – Commave v. Zevra - The National Law Review
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™ - GlobeNewswire
Investing in Zevra Therapeutics (NASDAQ:ZVRA) three years ago would have delivered you a 63% gain - Yahoo Finance
Zevra Therapeutics (NASDAQ:ZVRA) Trading 5.2% HigherHere's What Happened - MarketBeat
ZVRA Stock Price and Chart — NASDAQ:ZVRA - TradingView
Insider Buy: What is Zevra Therapeutics Incs market positionJuly 2025 Recap & AI Powered Market Entry Strategies - baoquankhu1.vn
Volume Recap: Will Zevra Therapeutics Inc benefit from geopolitical trendsEarnings Risk Report & Low Risk Growth Stock Ideas - baoquankhu1.vn
The Technical Signals Behind (ZVRA) That Institutions Follow - Stock Traders Daily
Published on: 2026-01-17 12:49:06 - baoquankhu1.vn
J.P. Morgan: Zevra Sees EU As Land Of Opportunity For Miplyffa - Citeline News & Insights
Zevra Therapeutics (ZVRA) Announces Positive New Data Supporting Foundational Role of MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C - MSN
Is Zevra Therapeutics (ZVRA) Using J.P. Morgan Spotlight To Reframe Its Rare-Disease Investment Story? - simplywall.st
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Zevra Therapeutics Reports Strong Q3 Earnings and Strategic Growth - MSN
Zevra Therapeutics FY 2024 Earnings Preview - MSN
Can Zevra Therapeutics Inc. stock withstand economic slowdownJuly 2025 Sentiment & Verified Entry Point Signals - Улправда
How Zevra Therapeutics Inc. stock benefits from tech adoptionJuly 2025 Rallies & Expert Approved Trade Ideas - ulpravda.ru
Can Zevra Therapeutics Inc. stock double in next 5 yearsJuly 2025 Gainers & Reliable Volume Spike Alerts - Улправда
Can Zevra Therapeutics Inc. stock sustain revenue growthTrade Performance Summary & Stock Market Timing Techniques - ulpravda.ru
Is Zevra Therapeutics Inc. stock a top pick in earnings season2025 Risk Factors & Fast Gain Swing Alerts - Улправда
Will Zevra Therapeutics Inc. stock deliver strong dividend growthWeekly Gains Report & Verified Momentum Stock Ideas - ulpravda.ru
What Wall Street predicts for Zevra Therapeutics Inc. stock priceAnalyst Downgrade & Precise Entry and Exit Recommendations - Улправда
Zevra Therapeutics Inc Azioni (ZVRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Zevra Therapeutics Inc Azioni (ZVRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sangiovanni Timothy J. | SVP, Finance & Corp Controller |
Feb 03 '26 |
Sale |
9.18 |
3,000 |
27,548 |
29,590 |
| Schafer Joshua | CCO |
Feb 03 '26 |
Sale |
9.19 |
10,500 |
96,500 |
62,278 |
| Sangiovanni Timothy J. | SVP, Finance & Corp Controller |
Jan 30 '26 |
Sale |
8.82 |
1,750 |
15,442 |
20,924 |
| Thompson Rahsaan | Chief Legal & Compliance |
Jan 30 '26 |
Sale |
8.83 |
4,080 |
36,010 |
49,919 |
| Quartel Adrian W | Chief Medical Officer |
Jan 30 '26 |
Sale |
8.83 |
4,533 |
40,036 |
9,723 |
| Schafer Joshua | CCO |
Jan 30 '26 |
Sale |
8.83 |
3,375 |
29,800 |
37,444 |
| McFarlane Neil F. | President and CEO |
Feb 02 '26 |
Sale |
9.38 |
91,000 |
853,425 |
364,350 |
0.36%
2.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):